Dr Reddy's completes acquisition of UK co Haleon's non-US …
WEB1 day ago · Hyderabad-based pharma giant Dr Reddy’s Ltd finalizes its largest acquisition by buying British Haleon Plc’s non-US nicotine replacement therapy (NRT) business for GBP 458 million. The deal includes brands like Nicotinell, thriving in 31 countries, and may involve contingent payments up to GBP 42 million. File photo.
Dr. Reddy's Laboratories Share Price Updates: Dr. Reddy's …
WEB19 hours ago · Dr. Reddy's Laboratories is currently priced at Rs 6713.35, showing a slight decrease of 0.57% today. The 7-day exponential moving average is Rs 6704.84.
Dr Reddy's completes acquisition of Haleon's NRT portfolio
WEB1 day ago · New Delhi: Dr Reddy's Laboratories on Monday said its Switzerland-based subsidiary has completed the acquisition of Haleon plc's global portfolio of consumer healthcare brands, outside of the US, in the Nicotine Replacement Therapy (NRT) category.
Dr. Reddy's Laboratories Stocks Live Updates: Dr. Reddy's …
WEB1 day ago · Explore the latest updates on Dr. Reddy's Laboratories stock, including: Last traded price 6745.0, Market capitalization: 112608.38, Volume: 1187, Price-to-earnings ratio 20.23, Earnings per share 333.59. Our liveblog combines fundamental and technical insights to offer a comprehensive overview of Dr. Reddy's Laboratories's performance.
Dr Reddy’s invests $620 million in Swiss subsidiary for
WEB4 days ago · Drug maker Dr Reddy's Laboratories Ltd on Friday (September 27) said it has invested $620 million in its wholly-owned subsidiary, Dr Reddy’s Laboratories SA, Switzerland (DRL SA).
Moving Averages Updates: Dr. Reddy's Surpasses 20-Day EMA, …
WEBSep 23, 2024 · Dr. Reddy's Laboratories has recently surpassed its 20-day Exponential Moving Average, with the current price standing at Rs 6653.35. This marks a notable increase of 1.56% for the day, while the 20-day EMA is recorded at Rs 6652.47, indicating a positive momentum in the stock's performance.
Dr. Reddy’s becomes first Indian pharma company to debut on …
WEBDec 14, 2023 · Dr. Reddy’s has become the first Indian pharma company to earn a place in the Standard & Poor Dow Jones Sustainability World Index (DJSI World) for 2023.
Dr. Reddy's Laboratories Announces the Appointment of Milan …
WEBHYDERABAD, India, May 28, 2024--Dr. Reddy's Laboratories Ltd. today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America.
India's Dr Reddy's expects healthy products pipeline in North …
WEBMay 7, 2024 · India's Dr Reddy's Laboratories expects a healthy products pipeline in its key North American market in the fiscal year 2024-25, the generic drugmaker said on Tuesday, after it reported a...
Dr. Reddy’s Q4 & FY23 Financial Results - Business Wire
WEBMay 10, 2023 · Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2023.